MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lite Strategy
LITS
|
+$34.4M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
+$2.51M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
+$2.01M |
| 4 |
Verastem
VSTM
|
+$1.17M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iTeos Therapeutics
ITOS
|
+$8.73M |
| 2 |
LHDX
Lucira Health
LHDX
|
+$4.39M |
| 3 |
EPZM
Epizyme
EPZM
|
+$2.15M |
| 4 |
Tectonic Therapeutic
TECX
|
+$1.02M |
| 5 |
Cytokinetics
CYTK
|
+$580K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
MPM BioImpact's Q4 2021 Portfolio in Review
As of Q4 2021, MPM BioImpact held 35 positions worth $549M, down 15% from $645M the previous quarter. Its ten largest holdings account for 73% of the portfolio.
MPM BioImpact's Q4 2021 filing shows 2 new, 2 increased, 22 reduced and 2 closed positions. Its largest new stake was Lite Strategy: 617,549 shares worth $33M. The largest sale was iTeos Therapeutics, an estimated $8.73M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.
- MPM BioImpact's largest Q4 2021 buy was Lite Strategy: 617,549 shares worth $33M.
- MPM BioImpact added most to Crinetics Pharmaceuticals in Q4 2021, an estimated $2.01M increase.
- MPM BioImpact's biggest Q4 2021 reduction was iTeos Therapeutics, cutting an estimated $8.73M.
- MPM BioImpact fully exited Lucira Health in Q4 2021, selling an estimated $4.39M.
- MPM BioImpact's ten largest holdings make up 73% of its $549M portfolio in Q4 2021.
- MPM BioImpact opened 2 new positions and closed 2 in Q4 2021.
- MPM BioImpact's portfolio value fell 15% quarter-over-quarter to $549M.
Based on MPM BioImpact's 13F filing for Q4 2021, filed 11 Feb 2022.